Search

Author/Creator Rothenstein, J.

1. A phase I study of binimetinib (MEK 162), a MEK inhibitor, plus carboplatin and pemetrexed chemotherapy in non-squamous non-small cell lung cancer. (July 2021)

Authors:
Fung, A.S.; Graham, D.M.; Chen, E.X.; Stockley, T.L.; Zhang, T.; Le, L.W.; Albaba, H.; Pisters, K.M.; Bradbury, P.A.; Trinkaus, M.; Chan, M.; Arif, S.; Zurawska, U.; Rothenstein, J.; Zawisza, D.; Effendi, S.; Gill, S.; Sawczak, M.; Law, J.H.; Leighl, N.B.
Journal:
Lung cancer
Issue:
Volume 157(2021)
Page Start:
21
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Randomized phase II study of modified FOLFOX-6 in combination with ramucirumab or icrucumab as second-line therapy in patients with metastatic colorectal cancer after disease progression on first-line irinotecan-based therapy. (22nd December 2016)

Authors:
Moore, M.; Gill, S.; Asmis, T.; Berry, S.; Burkes, R.; Zbuk, K.; Alcindor, T.; Jeyakumar, A.; Chan, T.; Rao, S.; Spratlin, J.; Tang, P. A.; Rothenstein, J.; Chan, E.; Bendell, J.; Kudrik, F.; Kauh, J.; Tang, S.; Gao, L.; Kambhampati, S. R. P.
Journal:
Annals of oncology
Issue:
Volume 27:Number 12(2016:Dec.)
Page Start:
2216
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search